Xconomy
MARCH 1, 2019
biopharmaceutical industry is dealing with unprecedented threats on several fronts: public backlash against high drug prices, slowing sales, and the possibility of more government regulation. After years of boom times, the U.S. In this Report, you’ll learn: The key indicators that suggest a possible downturn is on the way.
Xconomy
FEBRUARY 12, 2018
He vowed during last month’s State of the Union speech that drug prices “will come down.” ” Today, his administration’s fiscal 2019 budget proposal laid out what it calls a “comprehensive” strategy to lower drug prices.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
DECEMBER 21, 2018
It’s beginning to look a lot like, well, the last roundup of the year, with plenty of news to pack in before our holiday breather.
Both Sides of the Table
SEPTEMBER 15, 2022
<== Our conclusion was that this isn’t a temporary blip that will swiftly trend-back up in a V-shaped recovery of valuations but rather represented a new normal on how the market will price these companies somewhat permanently. We’ll just wait until companies that last raised in 2019 or 2020 come to market.” It’s just math.
Xconomy
APRIL 23, 2019
After a breakout year in 2017, the blockchain sector suffered a series of blows in 2018, from crashing cryptocurrency prices to increased regulatory scrutiny of crypto ventures and deepening skepticism about whether the technology was actually useful.
Xconomy
FEBRUARY 7, 2019
During the partial federal government shutdown in January, Gossamer announced it would pursue a little-used path to the public markets that required it to fix a share price, which was locked in for 20 days. The amount raised surpassed expectations.
Xconomy
JUNE 25, 2019
Even as Uber, Lyft, and other high-profile initial public offerings underperformed out of the gate, the average share price of companies that have gone public in the US this year is up by almost 33 percent. percent compared to their offer price at IPO. On average, those companies’ shares are up 32.6
Expert insights. Personalized for you.
83 
Let's personalize your content